(Total Views: 592)
Posted On: 07/09/2022 3:43:40 PM
Post# of 153908
if jonah sacha can deliver on a one time gene therapy injection for hiv to last a life time with leronlimab that will probably tko most of gileads biz after approval? what then should the value of leronlimab hiv be? lets say an easy $20 billion or more?
from seeking alpha
"Gilead produced $16.3 billion in sales from its HIV pipeline in FY21. The global market for HIV medications in FY21 was roughly $30.46 billion, giving Gilead control over 53% of the global HIV market. Of the top-ten leading medications for HIV on the market, Gilead produces six of them. The global HIV market is forecasted to be in the range of $45.5 billion by FY28. Should Gilead maintain a market share of 50% or more moving forward, it could produce roughly $23 billion in revenue from its HIV pipeline in FY28 alone."
from seeking alpha
"Gilead produced $16.3 billion in sales from its HIV pipeline in FY21. The global market for HIV medications in FY21 was roughly $30.46 billion, giving Gilead control over 53% of the global HIV market. Of the top-ten leading medications for HIV on the market, Gilead produces six of them. The global HIV market is forecasted to be in the range of $45.5 billion by FY28. Should Gilead maintain a market share of 50% or more moving forward, it could produce roughly $23 billion in revenue from its HIV pipeline in FY28 alone."
(3)
(0)
